Safety and pharmacokinetics of gb1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants

HIGHLIGHTS

• who: Vassilios Aslanis from the Galecto Biotech AB, Copenhagen N, Denmark have published the article: Safety and pharmacokinetics of GB1211, an oral galectin-3 inhibitor: a single- and multiple-dose first-in-human study in healthy participants, in the Journal: (JOURNAL)
• what: The authors report safety and pharmacokinetics (PK) of GB1211 in healthy participants. The authors report the results of a phase 1 trial of GB1211; the first clinical study of GB1211. The aim was to assess the safety and tolerability of single and multiple doses of GB1211.

SUMMARY

Department of . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.